Biochemically defined HIV-1 envelope glycoprotein variant immunogens display differential binding and neutralizing specificities to the CD4-binding site
about
A gp41 MPER-specific Llama VHH Requires a Hydrophobic CDR3 for Neutralization but not for Antigen RecognitionVaccine-elicited primate antibodies use a distinct approach to the HIV-1 primary receptor binding site informing vaccine redesignThermostability of Well-Ordered HIV Spikes Correlates with the Elicitation of Autologous Tier 2 Neutralizing AntibodiesProduction and preclinical evaluation of Plasmodium falciparum MSP-119 and MSP-311 chimeric protein, PfMSP-Fu24Elicitation of HIV-1-neutralizing antibodies against the CD4-binding site.HIV-1 envelope glycoprotein trimer immunogenicity elicited in the presence of human CD4 alters the neutralization profile.Unique C2V3 sequence in HIV-1 envelope obtained from broadly neutralizing plasma of a slow progressing patient conferred enhanced virus neutralization.Prime-boost immunization of rabbits with HIV-1 gp120 elicits potent neutralization activity against a primary viral isolate.Hyperglycosylated stable core immunogens designed to present the CD4 binding site are preferentially recognized by broadly neutralizing antibodies.Increased functional stability and homogeneity of viral envelope spikes through directed evolution.An HIV-1 envelope immunogen with W427S mutation in CD4 binding site induced more T follicular helper memory cells and reduced non-specific antibody responses.Pre-clinical development of a recombinant, replication-competent adenovirus serotype 4 vector vaccine expressing HIV-1 envelope 1086 clade C.Antigenicity and immunogenicity of a trimeric envelope protein from an Indian clade C HIV-1 isolate.Diverse antibody genetic and recognition properties revealed following HIV-1 envelope glycoprotein immunization.Immunogenic Display of Purified Chemically Cross-Linked HIV-1 Spikes.Broadly Neutralizing Antibody Responses in a Large Longitudinal Sub-Saharan HIV Primary Infection CohortBLyS-mediated modulation of naive B cell subsets impacts HIV Env-induced antibody responses.HIV-1 envelope trimer elicits more potent neutralizing antibody responses than monomeric gp120.Structural basis for germ-line gene usage of a potent class of antibodies targeting the CD4-binding site of HIV-1 gp120.Fusion proteins of HIV-1 envelope glycoprotein gp120 with CD4-induced antibodies showed enhanced binding to CD4 and CD4 binding site antibodies.Adjuvants may reduce in vivo transfection levels for DNA vaccination in mice leading to reduced antigen-specific CD8+ T cell responses.Longitudinal dynamics of the HIV-specific B cell response during intermittent treatment of primary HIV infectionA single residue within the V5 region of HIV-1 envelope facilitates viral escape from the broadly neutralizing monoclonal antibody VRC01.CD4 binding determinant mimicry for HIV vaccine design.Straightforward selection of broadly neutralizing single-domain antibodies targeting the conserved CD4 and coreceptor binding sites of HIV-1 gp120Conformational Epitope-Specific Broadly Neutralizing Plasma Antibodies Obtained from an HIV-1 Clade C-Infected Elite Neutralizer Mediate Autologous Virus Escape through Mutations in the V1 Loop.Design of an Escherichia coli expressed HIV-1 gp120 fragment immunogen that binds to b12 and induces broad and potent neutralizing antibodies.Anti-HIV B Cell lines as candidate vaccine biosensors.B cells from knock-in mice expressing broadly neutralizing HIV antibody b12 carry an innocuous B cell receptor responsive to HIV vaccine candidatesHIV-1 clade C escapes broadly neutralizing autologous antibodies with N332 glycan specificity by distinct mechanismsRobust neutralizing antibodies elicited by HIV-1 JRFL envelope glycoprotein trimers in nonhuman primates.High-resolution definition of vaccine-elicited B cell responses against the HIV primary receptor binding siteAntibody-based candidate therapeutics against HIV-1: implications for virus eradication and vaccine design.Bridging the past and the future of virology: surface plasmon resonance as a powerful tool to investigate virus/host interactions.Evolution of B cell analysis and Env trimer redesign.Persistence of VRC01-resistant HIV-1 during antiretroviral therapy.Targeted N-glycan deletion at the receptor-binding site retains HIV Env NFL trimer integrity and accelerates the elicited antibody response.Particulate Array of Well-Ordered HIV Clade C Env Trimers Elicits Neutralizing Antibodies that Display a Unique V2 Cap Approach.An HIV-1 Env-Antibody Complex Focuses Antibody Responses to Conserved Neutralizing Epitopes.The biological characteristics of predominant strains of HIV-1 genotype: modeling of HIV-1 infection among men who have sex with men.
P2860
Q27676864-9B214C06-0C7D-43A7-A127-EAF5D6A49614Q27681806-B584F5DA-12D2-43BC-84F3-463FBDC3B670Q28553360-69E58346-9E53-4F65-B9FB-7935F2993E32Q33743450-4BC088BE-902A-4809-9D60-261E6DACAD82Q34133551-9A71FC74-4089-4137-92D8-136E56AF4A35Q34399542-BF952587-9AFF-4698-A64E-78345974C83DQ34441935-3E062B05-5E24-49C6-94DC-5501C816CA9DQ34551010-DFA33061-C6ED-4F91-AC13-BBD432A81636Q34594905-8C00A4D4-E2DF-4735-A2A8-0DA58C057ED7Q34611144-CF6158EE-BE44-4C34-93BD-8C869163FD63Q34784825-BAF36CAA-7958-401F-9B6D-0A7996D41FA5Q35061529-A7D6842F-365A-406B-8A2A-003E60F33FC9Q35580892-7EE2521E-8CD0-4284-AB93-E55160AFA6D7Q35691113-144CD5AF-169C-4557-985B-16E4AFBA43D5Q35745442-FA0EFE06-D966-45FD-AE2C-E14B6B33F72FQ35894094-9824CC3C-BF9A-4E61-9BA1-9523BEAC00FFQ36016522-1C96F9A2-09AA-4C30-8F5A-FD956923B79EQ36132728-390E32D4-C3E8-48DF-8370-BA99A7DB7F91Q36132925-3B753520-2525-4E49-A3D0-5FFD1770A0C4Q36241267-57A17508-23ED-4FD5-A7B9-A74E3C4FE202Q36256253-F0C9CFDE-4425-43EA-8505-50694C4BE33AQ36309003-C181BF91-5C84-4C79-B148-D195810F6C0EQ36466846-8924165A-06B4-41A8-8184-BD0435EDB4C7Q36469664-D1EF5987-26E6-41A2-843A-BA8AC83E604CQ36559665-2EE5F00A-8D6D-45C9-A286-107A86AB56BCQ36694111-99D0B8AA-4C71-49CA-8C93-47AF8DEC00C1Q36742228-04955338-E299-4573-BD98-B368E768B13AQ36766704-E4CE0216-2D14-47BB-9EF2-1ED266BAE1ACQ37171260-AC1F12D9-65DA-41F7-B080-D01E3FA57C64Q37221386-787C88A2-2DDF-4AD6-9BC5-A36C972B9AF4Q37336704-0BD23421-A0D2-46A3-995D-8D8FE1A20FA8Q37735822-BDAB54D0-074B-46A5-BE64-E4E2B77428B2Q38072056-08CE86E3-08BD-48F0-8A60-DDEB87A2F8FFQ38141148-FDB93CE6-27B6-4EC1-A3B3-F7F835A91517Q38992740-43F3A3E8-CE35-419B-8DA1-99F1E23A3365Q39036775-3956F29F-107B-4577-808C-64D236932484Q40043429-CC7342CC-6E2D-446F-B6C5-29812B5F1648Q40198048-384F4034-0B6B-46FA-9527-E6CDDFF1E3A6Q40463159-7E21D674-EB80-4C9A-9A4C-94A0547A0F9FQ41500668-2BC86373-536B-463B-94AE-C04B58A74B4B
P2860
Biochemically defined HIV-1 envelope glycoprotein variant immunogens display differential binding and neutralizing specificities to the CD4-binding site
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Biochemically defined HIV-1 en ...... cities to the CD4-binding site
@ast
Biochemically defined HIV-1 en ...... cities to the CD4-binding site
@en
type
label
Biochemically defined HIV-1 en ...... cities to the CD4-binding site
@ast
Biochemically defined HIV-1 en ...... cities to the CD4-binding site
@en
prefLabel
Biochemically defined HIV-1 en ...... cities to the CD4-binding site
@ast
Biochemically defined HIV-1 en ...... cities to the CD4-binding site
@en
P2093
P2860
P356
P1476
Biochemically defined HIV-1 en ...... cities to the CD4-binding site
@en
P2093
Adhuna Phogat
Gunilla B Karlsson Hedestam
Karen Tran
Krisha McKee
Mattias N Forsell
Richard T Wyatt
Sijy O'Dell
Stephen D Schmidt
P2860
P304
P356
10.1074/JBC.M111.317776
P407
P577
2011-12-13T00:00:00Z